Minutes of Virtual Meeting of CMAAO NMAs on "Role of Baricitinib - JAK Inhibitor in moderate to severe Covid-19 & Country Updates" |
Editorial
eMediNexus Coverage from: 
Minutes of Virtual Meeting of CMAAO NMAs on "Role of Baricitinib - JAK Inhibitor in moderate to severe Covid-19 & Country Updates"

0 Read Comments                

5th June, 2021, Saturday, 9.30am-10.30amKey points from the discussion#1. JAK Inhibitor in moderate to severe Covid 19Dr Rohit Aggarwal, Medical Director, Arthritis and Autoimmunity Center, Professor of Medicine, University of PittsburghIn patients with severe COvid-19, the cytokine storm can cause significant lung damage; it can also damage other organs including the brain, kidneys and blood vessels via endothelial disruption and angiogenesis.The plasma levels of the proinflammatory cytokine IL-6 are raised; it is a prognostic indicator of mortality. It acts mainly through JAK/STAT pathway, which can be blocked by JAK inhibitors.All JAK inhibitors block different types of JAK receptors JAK, 1, 2,3 and Tyk 2. Different JAK inhibitors block different types of cytokines; the advantage of using JAK inhibitors are that they block multiple cytokines.Baricitinib is a JAK inhibitor. It has a du...
To Read or comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now